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Purpose: The official assay methods for most antiretroviral drugs are limited by cost and unavailability 
of good test equipment in several developing countries. Therefore, this study investigates the use of 
charge transfer complexation in the spectrophotometric assay of stavudine as an alternative method to 
conventional methods.  
Methods: Charge transfer complex formation between stavudine (n-donor) and chloranilic acid (π-
acceptor) in 1,4-dioxan using a spectrophotometer was employed. Thermodynamic parameters of the 
complex formed were determined. The proposed method was employed in the analysis of commercially 
available stavudine dosage form.  
Results: The wavelength of maximum absorption (λmax) of the complex was at 526 nm compared to 457 
nm for π-acceptor alone. Beer’s law was obeyed in the range of 5 - 40 mg % while the stoichiometry of 
the complex was found to be 2:1. The complex formed was still stable 24 h later. Its formation was 




J/mol. The standard entropy change was from 12.18 ± 0.78 to 
11.08 ± 1.23 cal/deg/mol over the temperature range of 30 - 60 
o





 over the same temperature range. The assay result of the standard stavudine 
solution was of high accuracy with a recovery value of 99.85 ± 1.95 %.  
Conclusion: The proposed method is reliable and reproducible and should be suitable for the quality 
control of stavudine in bulk and dosage forms. 
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INTRODUCTION 
 
Molecular interactions between electron 
donors and electron acceptors are generally 
associated with the formation of intensely 
colored charge-transfer complexes, which 
absorb radiation in the visible region [1]. 
Charge transfer complexes are formed 
between electron donors having sufficiently 
low ionization potential, and electron 
acceptors having sufficiently high electron 
affinity. The transfer of an electron from a 
donor to an acceptor is readily possible in the 
charge transfer process [2]. Chloranilic acid  
and a variety of other electron-accepting 
compounds have been reported to yield 
charge-transfer complexes leading to their 
utility in the development of simple and 
convenient spectrophotometric methods for 
the analysis of many drugs [3-8]. Such a 
complexation reaction is usually simple, fast, 
reproducible and reliable.  
 
Stavudine is a synthetic thymidine nucleoside 
analogue active against human 
immunodeficiency virus [9]. It contains in its 
molecular structure, basic centers with the 
availability of non-bonding electrons as 
donors. Stavudine has the structural formula 
presented in Fig. 1a while the structure of 
chloranilic acid is shown in Fig.1b.  
(a)   (b) 
 
Figure 1: Structure of (a) stavudine and (b) 
chloranilic acid 
 
High performance liquid chromatography 
(HPLC), thin layer chromatography, 
polarography, ultraviolet (UV) and infra-red 
(IR) spectrophotometry have been reported 
for the assay of stavudine [10]. Some of 
these techniques require complex procedure 
and instrumentation. For instance, HPLC 
methods generally require complex and 
expensive equipment, provision for use and 
disposal of solvents, labor-intensive sample 
preparation procedure and skilled personnel 
in chromatographic techniques [11]. Thus, 
the purpose of this study was to find a simple, 
rapid and reproducible method for the assay 
of stavudine which is an important drug in the 






The following materials were procured from 
local suppliers: two commercial stavudine 
capsule products - one (unbranded) from 
Strides Arcolab, India (40 mg/tab) and the 
other, Melxicap®  (40 mg/tablet, Evans 
Medical Plc, Lagos, Nigeria). The pure 
sample of stavudine was a gift from Arcolab 
through the Federal Medical Center, 
Abakaliki, Nigeria. Other materials used were 
1,4-dioxan (BDH, UK), methanol (Scharlau 
Chemie, S.A., Spain). All other reagents and 
solvents were of analytical grade and used as 
received. All laboratory reagents were freshly 
prepared. 
 




A stock solution of chloranilic acid (3.5×10
-3 
M) was prepared by dissolving 0.073 g of 
chloranilic acid powder, accurately weighed, 
in 1, 4-dioxan and making up to 100 ml with 
the same solvent. Further dilutions were 





A standard stock solution of stavudine in 
methanol was prepared by dissolving 1.26 g 
of stavudine powder in methanol in a 100 ml 
volumetric flask and made up to volume with 
the same solvent to provide a 5.6× 10
-2 
M 
solution. Further dilutions were carried out 
using methanol to obtain lower 
concentrations. 
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Absorption spectrum of chloranilic acid 
 
Chloranilic acid (2 ml) stock solution was 
scanned in a spectrophotometer (UNICO 
2102 PC, USA) in the wavelength range of 
400 - 700 nm to determine its wavelength of 
maximum absorption. 
 
Absorption spectrum of stavudine-chloranilic 
acid complex 
 
Chloranilic acid (2 ml) stock solution (3.5×10
-3
 
M) was mixed with 2 ml of stavudine (5.6× 10
-
2 
M) solution. The contents were mixed and 
left at room temperature for 1 h. A colour was 
developed and the complex formed was 
scanned spectrophotometrically against the 
blank of dioxan and methanol in the 
wavelength range of 400-700 nm. 
 
Beer’s calibration plot for the stavudine-
chloranilic acid complex 
 
Serial volumes (ranging from 0.4 to 2.8 ml) of 
the stock stavudine solution (5.6×10
-2
 M) in 
0.4 ml steps were transferred to different test 
tubes. Sufficient volumes of methanol were 
added to bring the volume in each test tube 
to 3 ml; 2 ml of chloranilic acid (3.5×10
-3
 M) 
was added to each of the test tubes to afford 
a final concentration range of 2.24 x 10
-2
 M - 
1.56 x 10
-1
 M. The contents were mixed and 
left at room temperature for 1 h. The 
absorbance of each sample was determined 
at the wavelength of maximum absorption 
(λmax of 526 nm) against blank of 1, 4-dioxan 
(2 ml) and methanol (3 ml).  
 
Time - absorbance relationship 
 
A time - absorbance relationship was esta-
blished for the complex to determine the time 
the complex will take to develop fully. Equal 
volumes (2 ml) and equimolar concentrations 
(5.0×10
-3
 M) of the drug and chloranilic acid 
were mixed and absorbance taken at various 
time intervals from 0 to 18 min at 526 nm. 
 
Determination of stoichiometry of the 
complex 
 
Job’s method of continuous variation was 
employed [12]. Equimolar concentrations 
(3.0×10
-2
 M) of solutions of stavudine and 
chloranilic acid were used for the experiment. 
A series of 5 ml volumes of mixtures of the 
above solutions comprising complementary 
proportions of the two solutions in various 
ratios ranging from 0.5:4.5 to 4.5:0.5 
(chloranilic acid: stavudine solution) were 
transferred into different test tubes and the 
complex formed for each reaction mixture 
was allowed to stand for 1 h at room 
temperature before analysis at 526 nm. A 
blank solution consisting of chloranilic acid (2 
ml) and methanol (3 ml) was used. 
 
Determination of stability constant, molar 
absorptivity and thermodynamic 
parameters 
 
Serial volumes of 3.0×10
-2
 M solution of 
stavudine ranging from 0.4 to 2.8 ml, in 0.4 
ml steps, were transferred to different test 
tubes. The solutions were diluted to 3 ml with 
methanol and 1 mL of a 3.0×10
-2
 M solution 
of chloranilic acid in 1, 4-dioxan was added to 
each test tube. The contents were capped 
and mixed by gentle shaking. The test tubes 
were allowed to stand for 1 h at room 
temperature (30 
o
C), and absorbance 
measurements were taken 
spectrophotometrically at 526 nm against a 
blank of methanol and dioxan. Further 
analyses of the reaction mixtures were 
carried out at temperatures of 40, 50 and 60 
o
C, respectively. The molar absorptivity, 
thermodynamic parameters and association 
constant for the stavudine-chloranilic acid 
complex were evaluated using the Benesi-
Hildebrand equation
 
(Eq 1) [13] and the data 
are shown in Table 1.  
 




where [Do] and [Ao] are initial concentrations 
of the reactants, Aλ
[A:D]
 is the absorbance of 
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the complex at 526 nm, Eλ
[A:D]
  is the molar 
absorptivity of the complex at 526 nm, and 
Kc
[A:D
 is the stability constant. The regression 
equations for the plots at the temperatures of 
30, 40, 40 and 60 
o
C were found as follows, 
Y= 0.7264x + 0.9307 (R
2
=0.9854), 0.6064x + 
1.0713 (R
2
=0.963), 0.5826x + 0.989 
(R
2





 values, which were all 
above 0.9, indicate very good correlations 
suggesting dependable data from the 
experiment. The intercepts and slopes of the 
regression lines from a plot of [Do][Ao]/A λ
[A:D]
 
against 1/[Do]  were used to calculate the 
values of E λ
[A:D]
 and  Kc
[A:D]
 respectively. The 
intercepts and slopes of the regression lines 
from a plot of [Do][Ao]/A λ
[A:D]
 against 1/[Do]  





 respectively.  The data obtained 
for the stability constants at different 
temperatures were further utilized to calculate 
the standard enthalpy change (∆H
 o
) using Eq 
2. 
    
 ……. (2) 
 
where R is the gas constant. The ∆H
o
 of the 
stavudine-chloranilic acid interaction was 
obtained from Eqn. 2 by plotting log Kc
[A:D]
 
against the reciprocal of absolute 
temperature T, where it was calculated from 
the slope of the regression line. 
Also Gibb’s free energy (∆G
o
) and the 
entropy (∆S
o
) were calculated respectively 
from Eqn. 3 and Eqn. 4, and the results 






 ……………….Eqn. 3 









Assay procedure for stavudine capsule 
 
Twenty stavudine capsules (Strides Arco 
Lab.) were emptied, thoroughly mixed by 
trituration in a mortar and an amount 
equivalent to 717.4 mg of active drug was 
accurately weighed. This was mixed with 
methanol in a 100 ml flask to extract the 
active drug. The mixture was filtered to 
remove the excipients after shaking for 30 
min. The filtrate was thereafter made up to 
100 ml with methanol to provide a theoretical 
concentration of 3.2×10
-2 
M of stavudine 
solution. Serial volumes (0.7, 1.4, 2.1, 2.8 
and 3.5 ml) of the solution were transferred 
into different test tubes to give concentrations 
of 5, 10, 15, 20 and 25 mg (as used in the 
Beer’s plot), respectively. Sufficient methanol 
was added in each case to bring the volume 
to 4 ml. Chloranilic acid solution (3.5×10
-3 
M, 
1 ml) was then added in each case to bring 
the final volume to 5 ml each. The contents 
were mixed, left for 1 h at room temperature 
and their absorbance determined at 526 nm 
against a blank of methanol and dioxan. The 
procedure was repeated five times. Percent 
recovery of stavudine from the dosage form 
was calculated by reference to its Beer’s plot. 
This was repeated for the other brand of 




The data obtained were analysed by SPSS 
version 11 and recorded as mean ± standard 
deviation (SD, n = 5). Statistically significant 
difference between brands of stavudine 
assayed by the proposed method was 
evaluated using the Students’ t-test and one-
way analysis of variance (ANOVA; Fischer 
LSD post-hoc test). Significant differences 






A solution of chloranilic acid in 1, 4-dioxan 
produced a golden yellow colour with 
maximum wavelength of absorption at 457 
nm (Fig 2). Instantaneous purple color was 
obtained on reaction of the yellow chloranilic 
acid solution with the solution of the 
stavudine in methanol.  
 
The results show that the absorbance of the 
complex was high at zero time and increased 
slowly over the 200 min period of 
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investigation (Fig. 3). The colour of the 























Figure 2: Absorption spectra of chloranilic acid 
(dotted line) and stavudine–chloranilic acid 

















Figure 3: Time-absorbance relationship for 
stavudine-chloranilic acid complex 
 
Beer’s law was obeyed by the complex. At 
526 nm, a fairly linear relationship was 
obtained (r
2
 = 0.8469) between the 
absorbance and the concentration over the 
entire range studied (5 - 40 mg/100 ml of 
stavudine). The regression equation of the 
line, derived by the method of least squares, 
is as shown in Eq 5. 
 
A526 nm = 0.0259C + 0.00 ……………. (5) 
 
where C is the concentration (mg %) of 
stavudine-chloranilic acid complex. The 
correlation is fairly high.  
 
Job’s plot for stavudine-chloranilic acid 
complex 
 
The stoichiometry of the stavudine-chloranilic 
acid complex was studied using Job’s 
method of continuous variation.
 
Its Job’s plot 
























Figure 4: Job's plot of continuous variation for 
stavudine-chloranilic acid complex 
 
Stability constant, molar absorptivity and 
thermodynamic parameters 
 
The molar absorptivity, thermodynamic 
parameters and association constant for the 
stavudine-chloranilic acid complex were 
evaluated using the Benesi-Hildebrand 
equation
 
(Eq 1) [13] and the data are shown 
in Table 1. The high negative ∆H value 
(exothermic) of this complex suggests 
spontaneity of the complexation process. The 
entropy is high supporting the above 
assertion. The direct relationship between 
molar absorptivity and temperature indicates 
that the formed complex is strong and not 





The recovery results of stavudine from the 
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30 244678.25 -7470.19   67.11 
40 210172.34 -7622.19 -3778.96 11.62 77.52 
50 152322.92 -7659.10   101.01 
60 127032 -7776.09   123.46 
      
showed that recovery was 105.2 ± 10.3 and 
122.8 ± 6.03 % (n = 5) for stavudine from the 
two commercial products, unbranded and 
Melxicap
®
, respectively. The recovery 
experiment on the standard stavudine 
solution gave a value of 99.85 ± 1.95 (n=5). 
These values were not statistically different (p 




The sharp change in colour from yellow in the 
chloranilic acid alone to purple in the complex 
with a bathochromic shift in absorption 
maxima (457 nm to 526 nm) suggests a 
charge transfer complex formation (see Fig 
2).  In charge transfer complexation, the 
absorption maxima of the complexes formed 
are often shifted some nanometers to the 
longer wavelength side of the absorption 
band (bathochromic shift) of either of the 
components. This shift has been observed 
between chloranilic acid and other drugs [14]. 
The time - absorbance relationship of the 
complex suggests that the formation of the 
stavudine–chloranilic acid complex was 
instantaneous and the complex was stable 
for over 24 h with the purple colour still 
evident.  
 
The complex obeyed Beer’s law in the 
concentration range of 5 - 40 mg % with fair 
correlation. This conformity with Beer’s law 
indicates that spectrophotometric analysis of 
electron donor-acceptor formation can be 
used for the quantitative analysis of 
stavudine. Interestingly, the correlation was 
fairly high indicating reliability. The 
stoichiometry, which was 2:1 (stavudine: 
chloranilic acid) for the complex, indicates the 
presence of two strong electron-accepting 
sites for chloranilic acid. 
 
The stability constants presented were high 
and showed a reduction with increase in 
temperature. This is probably due to the 
dissociation of the complexes at higher 
temperatures [14]. It follows that although the 
complex can be regarded as thermostable, it, 
however, showed higher stability at lower 
temperature. The molar absorptivity values 
increased with increase in temperature; an 
interesting discovery which suggests that the 
complex was fairly strong enough to 
withstand elevated temperature conditions. 
Thus, with increase in temperature, 
dissociation of the complex was gradually 
activated leading to lower concentration of 
the complex in the reaction medium [14].  
 
Free energy and the entropy changes 
showed negative and positive values, 
respectively. This indicates the spontaneity of 
the reaction. In fact, the instantaneous 
formation of the complex confirms this. High 
negative value of the standard enthalpy 
change (∆H
o
) together with association 
constant values indicate strong bonding 
between chloranilic acid and stavudine as 
well as high stability of the resultant charge-
transfer complex.  
 
In terms of the recovery, there was no 
statistically significant difference (p < 0.05) 
between the two brands (105.2 ± 10.3 and 
122.8 ± 6.03). Although the results showed 
high quantitative recoveries, the standard 
deviation values were high suggesting that 
larger data may be used for validation of the 
proposed process. Thus, the proposed 
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method gives very near values according to 
the label claims and further confirms a fair 
accuracy of the method. This result was not 
affected by the presence of excipients in the 
capsule since the excipients were removed 
before analysis. The proposed method is 
simple, low-cost and rapid compared to other 





Charge transfer complexation between 
stavudine and chloranilic acid occurred with a 
2:1 stoichiometry, with maximum absorption 
at 526 nm. Thermodynamically, the complex 
possessed high stability constant, and was 
still stable after 24 h. This method was used 
to successfully assay stavudine in a tablet 
dosage forms. However, the precision and 
accuracy of the proposed method should be 
determined to enable an unbiased 
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